Your browser is no longer supported. Please, upgrade your browser.
APM Aptorum Group Limited daily Stock Chart
Aptorum Group Limited
Index- P/E- EPS (ttm)-0.53 Insider Own29.39% Shs Outstand28.97M Perf Week9.63%
Market Cap761.91M Forward P/E- EPS next Y-0.54 Insider Trans- Shs Float4.00M Perf Month-7.95%
Income-14.80M PEG- EPS next Q- Inst Own0.02% Short Float0.43% Perf Quarter98.94%
Sales0.40M P/S1904.78 EPS this Y-462.50% Inst Trans22.20% Short Ratio2.09 Perf Half Y94.67%
Book/sh1.19 P/B22.10 EPS next Y- ROA- Target Price28.50 Perf Year-
Cash/sh0.45 P/C58.61 EPS next 5Y- ROE- 52W Range11.80 - 33.28 Perf YTD73.25%
Dividend- P/FCF- EPS past 5Y- ROI-23.80% 52W High-20.67% Beta-
Dividend %- Quick Ratio2.40 Sales past 5Y- Gross Margin17.10% 52W Low123.73% ATR1.66
Employees39 Current Ratio2.40 Sales Q/Q- Oper. Margin- RSI (14)55.43 Volatility3.29% 6.09%
OptionableNo Debt/Eq0.31 EPS Q/Q- Profit Margin- Rel Volume0.46 Prev Close26.30
ShortableNo LT Debt/Eq0.00 Earnings- Payout- Avg Volume8.27K Price26.40
Recom2.00 SMA20-5.27% SMA5017.10% SMA20050.17% Volume1,310 Change0.38%
Jun-26-19 11:05AM  APM: Aptorum Focused on Development of Diseases with Significant Global Unmet Needs Zacks Small Cap Research
May-22-19 08:00AM  Aptorum Group to Be Newly Added to MSCI HK Micro Cap Index Business Wire
May-15-19 09:00PM  Aeneas Capital and Pyrinas Target Launch of US$120m Fund to Develop Co-Working Laboratory Ecosystems for Life Sciences Start-Ups in the United States Business Wire
May-07-19 07:19AM  What Percentage Of Aptorum Group Limited (NASDAQ:APM) Shares Do Insiders Own? Simply Wall St. +10.76%
May-06-19 08:00AM  Aptorum Groups Subsidiary - Claves Life Sciences Limited Establishes Novel Therapeutic Platform for Treatment of Various Diseases via Modulation of the Chemical Signaling Relating to Gut Microbiota Business Wire
Apr-30-19 10:42AM  UPDATE - Argus Research Initiates Equity Research Report Coverage on Aptorum Group Limited (NasdaqGM: APM) GlobeNewswire
Apr-24-19 08:00AM  USD$90 Million Initiative between A*Star, Aptorum Group and Aeneas Capital to Drive Healthcare Innovations Business Wire
04:30AM  Aptorum Groups Smart Pharma announces launch of its asset backed Smart Pharma token (SMPT), supported by its computational repurposed drug discovery platform Smart-ACT Business Wire
04:30AM  Aptorum Group Establishes Smart Pharma to Focus on Computational Repurposed Drug Discovery for Orphan and Unmet Diseases Business Wire
04:15AM  Aptorum Group Limited Announces Repurchase of USD13,500,000 Outstanding Convertible Bonds Due 2019 Business Wire
Apr-15-19 09:55AM  Aptorum Group Limited Reports 2018 Fiscal Year Financial Results and Business Update Business Wire
Apr-01-19 09:30AM  Aptorum Group Limited Announces Appointment of Head of R&D and Chief Operating Officer Business Wire
Mar-08-19 02:49PM  Aptorum Group Limited to Present at the Barclays Global Healthcare Conference 2019 Business Wire
Mar-04-19 11:26AM  Aptorum Group Limited to Present at the Barclays Global Healthcare Conference 2019 Business Wire
Feb-25-19 05:28AM  BRIEF-APM Automotive Posts Qtrly Net Profit Of 17.3 Million RGT Reuters
Dec-07-18 02:07AM  Aptorum Group Limited Announces Pricing of Initial Public Offering Business Wire
Feb-28-18 05:20AM  BRIEF-APM Automotive Holdings Posts Qtrly Net Profit 13.1 Million RGT Reuters
Aptorum Group Limited, a pharmaceutical company, develops and commercializes a range of therapeutic and diagnostic technologies to treat unmet medical needs. It focuses on developing various drug molecules and certain technologies for the treatment and diagnosis of human disease conditions in neurology, infectious diseases, gastroenterology, oncology, and other disease areas. The company also focuses on the development of surgical robotics and medical devices; and operating outpatient clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in Central, Hong Kong.